Dysphagia Affecting Quality of Life in Cerebellar Ataxia—a Large Survey

M. Rönnefarth 1 · N. Hanisch 1 · A. U. Brandt 2 · A. Mähler 3 · M. Endres 1,2 · F. Paul 1,2,3 · Sarah Doss 1,4

Published online: 13 March 2020 © The Author(s) 2020

Abstract
Dysphagia is a common symptom in neurodegenerative disorders and is generally associated with increased mortality. In the clinical care setting of ataxia patients, no systematical and standardized assessment of dysphagia is employed. Its impact on patients’ health-related quality of life is not well understood. To assess the impact of dysphagia in ataxia patients on diet, body weight, and health-related quality of life. We conducted a large survey using self-reported questionnaires for swallowing-related quality of life (Swal-QOL) and a food frequency list in combination with retrospective clinical data of 119 patients with cerebellar ataxia treated in the neurological outpatient clinic of a large German university hospital. Seventeen percent of ataxia patients suffered from dysphagia based on the Swal-QOL score. Less than 1% of all patients reported dysphagia as one of their most disabling symptoms. Dysphagia was associated with unintentional weight loss ($p = 0.02$) and reduced health-related quality of life ($p = 0.01$) but did not affect individual nutritional habits ($p > 0.05$; Chi-squared test). Dysphagia is a relevant symptom in cerebellar ataxia. A systematic screening for dysphagia in patients with cerebellar ataxia would be desirable to enable early diagnosis and treatment.

Keywords Dysphagia · Cerebellar ataxia · Health-related quality of life · Spinocerebellar ataxia · Nutrition

Introduction
Dysphagia is a common symptom in patients suffering from neurodegenerative disorders that affect motor control. In ataxia disorders, studies on prevalence, consequences, and prognostic implications of dysphagia are scarce. Cerebellar ataxia arises from different etiologies, classified as hereditary or sporadic. For spinocerebellar ataxia (SCA), the reported prevalence of dysphagia varies considerably from 6 to 74%, depending on several factors including the underlying genetic mutation with lower prevalence in pure cerebellar syndromes, e.g., in SCA 6 [1–5].

Symptoms in cerebellar ataxia comprise gait unsteadiness, limb ataxia, dysarthria, dizziness, and dysphagia [6]. While gait and speech disorders in chronic disease are known to deteriorate health-related quality of life (HRQOL) [7, 8], a link between dysphagia and HRQOL has not been investigated yet. Neurogenic dysphagia impedes food consumption and may lead to weight loss, malnutrition, and dehydration [4, 9, 10]. More drastically, it may cause life-threatening aspiration and pneumonia with increased morbidity and mortality [8, 11, 12]. A post mortem pathologic study reported neurodegeneration of the brainstem nuclei to be involved in ingestion as well as aspiration pneumonia to be the major cause of death in patients suffering from SCA-3 [13]. In SCA, every phase of the swallowing process (lingual, pharyngeal, and esophageal phase) can be impaired [14].

Reduced quality of life accompanies the progression of chronic neurological diseases, but it remains unclear which factors determine the individual quality of life in ataxia patients [7, 15].

To prevent complications, early detection of swallowing disorders is important. Furthermore, identification of influencing
factors on HRQOL is crucial for individualized and specific treatment. It remains unclear if swallowing disorders in cerebellar ataxia affect patients’ nutritional habits and are related to complications such as weight loss and lower body weight.

To discern factors influencing HRQOL and dysphagia-related consequences in daily life, we conducted a written survey in a clinically well-characterized large patient cohort suffering from progressive cerebellar ataxia of various origins. To screen for swallowing deficits and their influence on quality of life, we used the Swal-QOL, a validated, widely used, subjective assessment tool [16]. The food-frequency list (FFL) was used to assess individual nutritional habits [17].

Materials and Methods

Study Design and Patients

For this cross-sectional observational study, we screened patients regularly attending the ataxia outpatient clinic of a large university hospital (Charité-Universitätsmedizin Berlin, Germany) from November 2011 to April 2014. Inclusion criteria were progressive ataxia not related to an acute event as defined by an experienced clinical assessor and willingness to participate in the study. We excluded patients with dementia or progressive cognitive decline. During routine clinical care visits, we assessed clinical parameters and—if indicated—genetic testing. Patients identified by the above-mentioned procedure (n = 190) received questionnaires and patient information together with the written informed consent by regular mail. Seventy-one percent of the questionnaires were answered and returned (n = 133). After exclusion of datasets with missing informed consent form (12) and incomplete data (2), questionnaires with complete Swal-QOL were included in the analysis (two excluded).

Table 1 refers to patient characteristics in the study cohort. We classified ataxia as hereditary, sporadic, or unknown. Patients suffering from hereditary ataxia had either positive genetic testing or a family member with genetically confirmed hereditary ataxia or strong clinical suspicion of hereditary ataxia based on pedigree, clinical presentation, and exclusion of other etiologies. Of the hereditary ataxias, 42 were autosomal dominant (28 patients with SCA 1–3, SCA 6, or SCA 17; 12 patients with SCA 11, 14, 27, or 28; two patients with Episodic Ataxia type 2 (EA2)), three recessive (one patient with ataxia telangiectasia and two patients classified as recessive according to pedigree analysis), and one mitochondrial ataxia. Among the sporadic ataxias, diagnosis of sporadic ataxia with onset in adulthood (SAOA) was established for 33 patients and criteria for multiple system atrophy with predominant cerebellar ataxia (MSA-C) were fulfilled in nine patients [18]. Other causes were autoimmune (n = 9) and toxic related to alcohol abuse (n = 6). In 16 patients classified as unknown, genetic testing for SCA 1–3, SCA 6, and Friedreich’s ataxia was negative and clinical signs for autonomic dysfunction were missing.

The local ethics committee at Charité-Universitätsmedizin Berlin (EA1/185/13) approved the study and it was conducted according to the 1964 Helsinki declaration in its currently applicable version. All participants gave written informed consent as described above.

General Design of the Survey

The survey included general questions about age, gender, body weight, and height. Patients were asked to name their most impairing symptoms and the age, when first symptoms were noticed [19]. A 5-point Likert scale assessed mobility, rating the maximal walking distance (if needed with the help of two persons): 0: < 200 m, 1: < 500 m, 2: < 1 km, 3: < 5 km, 4: > 5 km. To assess potential weight loss, patients reported if and how much weight they had lost in the past 12 months, if it had been unwanted (yes/no), if the patient had experienced reduced appetite (yes/no), and if the amount of food intake had been reduced in the last 12 months (yes/no). Ongoing therapy was defined by the time spent with physical, speech, and occupational therapies weekly. To assess overall impact of disease on quality of life, patients should report impairment of their subjective quality of life by the disease on an 11-point Likert scale: 0: strong impairment and 10: no impairment at all. To control for unspecific effects of pathologic fatigue and depressive symptoms, the self-reported Fatigue Severity Score (FSS, a score > 5 indicating pathologic fatigue) and Becks Depression Inventory (BDI-II, scores between 14 and 19 indicating mild, 20–28 indicating moderate, and above 29 indicating severe depression) were included in the questionnaire [20, 21].

Assessment of Dysphagia

The swallowing quality of life questionnaire (Swal-QOL) was used to assess dysphagia and related quality of life (QOL) using a validated German version of the questionnaire [16, 22, 23]. The Swal-QOL is a reliable and valid self-assessment tool covering all WHO ICF domains [24]. It comprises 44 items assessing 10 swallowing-related QOL domains: food selection, burden, mental health, social functioning, fear, eating duration, eating desire, communication, sleep, and fatigue. Additionally, 14 items focus on symptoms related to swallowing deficits; three questions evaluate nutritional intake (presence of percutaneous endoscopic gastrostomy (PEG) (yes/no), food, and liquid consistency) and one question addresses general health. Each item is rated on a 5-point Likert scale. After linear transformation, domain scores and a total score from 0 to 100 (100 indicating the most favorable state) are calculated. We used a seven-domain total score to
identify patients with swallowing difficulties (scoring below 70). It comprises the first seven domains and reliably reflects swallowing-related QOL [16, 25]. Patients scoring below 70 are classified as dysphagic throughout the manuscript. Patients were allowed to fill out the questionnaire with the help of a proxy, which was reported by four patients (physical impairment, e.g., limb ataxia). Eleven patients were supported by a trustworthy person, e.g., a family member.

**Assessment of Nutritional Habits**

The self-reported Food-Frequency-List (FFL) of the MONICA project assessed individual nutritional habits, including 16 food categories based on the guidelines of the German Nutrition Society (DGE) [16, 17]. The mean weekly food intake frequency of, e.g., ‘meat (excluding sausage)’, ‘curds, yoghurt, sour milk’, ‘mineral water’, ‘fresh fruit’, and others were rated optimal, normal, or unfavorable. The FFL uses a six-point Likert scale to report frequency ranging from “almost daily intake” to “never”. Results are rated according to the method proposed by Winkler and coworkers [17]: each item is regarded separately, e.g., daily intake of mineral water is rated optimal whereas daily meat intake is rated unfavorable. With a maximum score of 32, 14–15 indicates normal food intake while lower scores are regarded as unfavorable and higher scores as optimal food intake habits.

**Data Analysis**

We used SPSS Version 22 (IBM Corp, Armonk, NY, USA) for data analysis. Figures were created using MATLAB2008b with Statistics Toolbox Release 2012b (The MathWorks Inc., Natwick, MA, United States). To test for differences between dysphagic and non-dysphagic patients regarding diagnosis, gender, disease duration, therapies, body weight, FSS, and BDI-II mean scores, we used Mann-Whitney U test. For differences between dysphagic and non-dysphagic patients regarding weight loss, intention to lose weight, and reduction in appetite or food intake, we used Chi-squared test. For correlation between dysphagia and etiology, age, gender,
disease duration, weight loss, body weight, mobility, quality of life, fatigue, depression, and nutritional habits, we calculated Spearman’s correlation coefficient.

We used multiple linear regression analysis to investigate the association of disease duration, etiology, mobility, FFL, Swal-QOL, FSS, and BDI-II classification on the variance of the self-reported QOL scale.

Significance level was established at \( p < 0.05 \) and adjusted for multiple testing for correlation analysis at \( p = 0.0045 \).

### Results

**Dysphagia as Self-reported Main Symptom Versus Swal-QOL**

A single patient reported dysphagia as part of his most disabling symptoms. In total, 20 different symptoms were mentioned (Fig. 1). This patient also reported pain, had a gastric feeding tube, and suffered from underweight (BMI = 17.6 kg/m²). Dysphagia was evident in his Swal-QOL total domain score (14.2) as well. This patient reported symptoms related to saliva and to pharyngeal but not oral phase in the questionnaire.

Furthermore, more than 75% of all patients reported gait instability and almost one third reported dysbalance. Each, dysarthria, vertigo, and limb weakness were reported by more than 10% of the patients. Patients reporting dysarthria as their most disabling symptom \((n = 26)\) did not mention additional dysphagia and they did not show reduced body weight (mean BMI = 27 kg/m² ± 5). Swal-QOL mean domain score in dysarthric patients was 82.9 ± 18.4 with six patients rated as dysphagic.

Twenty patients presenting significant dysphagia were identified using a cut-off of 70 in the Swal-QOL total domain score \([16, 25]\). For detailed patient characteristics, please refer to Table 1. Patients with dysphagia more often reported to regularly attend speech and occupational therapy than those without. Dysphagic patients were more fatigued and depressed than patients without dysphagia \((U = 1656, \ p = 0.001 \) for FSS and \( U = 1784, \ p < 0.001 \) for BDI-II; compare Table 1).

The Swal-QOL domain score differences between dysphagic and non-dysphagic patients are shown in Fig. 2. Scores were significantly different between groups for all domains except sleep (Mann-Whitney \( U \) test \( p < 0.003 \) for fatigue; \( p < 0.001 \) for the remaining domains). Duration of food intake and social function of eating were most compromised in the dysphagic group, whereas the desire to eat was less affected. Patients without dysphagia almost reached the same score as a healthy control group (Fig. 2c).

The dysphagia phenotype comprised all three phases of swallowing (pharyngeal, oral, and saliva-related) according to the 14 Swal-QOL items differentiating dysphagic disorders (data not shown). Coughing was the most commonly reported symptom in patients with dysphagia. No different phenotype was seen in dysphagic patients reporting speech disorders.

High scores on the Swal-QOL were associated with high mobility levels and high self-reported QOL while lower scores were associated with fatigue and depression. There was a positive correlation of Swal-QOL total domain score with mobility \((\rho = 0.31, \ p < 0.001)\) and QOL \((\rho = 0.39, \ p < 0.001)\) and a negative correlation with fatigue \((\rho = -0.39, \ p < 0.001)\) and depression \((\rho = -0.38, \ p < 0.001)\). There was no significant correlation of the Swal-QOL with etiology, age, gender, body weight, weight loss, disease duration, or nutritional habits.
Body Weight and Nutrition

Twenty-one patients (seven with dysphagia) reported weight loss of more than 3 kg in the past 12 months while 14 describing it as unintentional (Fig. 3c and d). All dysphagic patients in comparison to half of the non-dysphagic patients stated their weight loss to be unintentional (χ² = 5.2, p = 0.02). There was no difference between groups regarding change in appetite or reduction of food intake (Fig. 3d).

Dysphagic patients more often reported a reduced food intake (45%) as compared to non-dysphagic patients (26%; χ² = 4.2, p = 0.04) but body mass index (BMI) was similar in both groups. According to their BMI, seven patients (four of them with dysphagia) were classified as underweight, 49 (seven dysphagic) as normal weight, and 61 (nine dysphagic) as overweight (Fig. 3a).

Furthermore, no difference in nutritional habits in dysphagic as compared to non-dysphagic patients was verified among the 116 patients, for which FFL data was available (Fig. 3b). Scores for all patients ranged from 7 to 24 points with a mean of 14.5 ± 3.8. Forty-eight patients (41%) showed favorable, 25 (21%) normal, and 45 (38%) unfavorable nutritional habits. Dysphagic patients (n = 20) had a mean score of 13.1 ± 3.8; non-dysphagic patients (n = 96) had a mean score of 14.8 ± 3.7.

Quality of Life

Dysphagic patients reported significantly lower quality of life scores (mean = 1.9 ± 2.2) than non-dysphagic patients (mean = 3.3 ± 2.4; U = 839.5, p = 0.01). Multiple linear regression analysis showed that greater mobility and higher Swal-QOL scores were associated with a higher quality of life (p = 0.00001, F = 13.16, adjusted R² = 0.18, RMSE = 2.12; Fig. 4). No association for presence of fatigue or depression, disease duration, etiology, and nutritional habits (FFL) was seen in the regression analysis.

Discussion and Conclusion

In our cohort, cerebellar ataxia patients hardly reported dysphagia as cardinal symptom in contrast to a considerable (17%) proportion identified as dysphagic by the Swal-QOL. Dysphagia was linked to unintentional weight loss, whereas nutritional habit changes did not become apparent. Apart from the well-established mobility decrease, we also found dysphagia to be associated with a reduced health-related quality of life (HRQOL) in patients with ataxia.

Among the 20 patients with dysphagia identified by the Swal-QOL, the only one deliberately reporting dysphagia as cardinal symptom was a patient with gastric tube and severe weight loss indicating a late stage of dysphagia. It would be useful to identify patients with dysphagia earlier, when unintentional weight loss is yet to be prevented. To this end, a standardized screening in the regular neurological care setting would be preferable before patients are referred to phoniatric consultation with videofluoroscopy. The widely varying prevalence of dysphagia reported in cerebellar ataxia reflects the underlying disease pathology and assessment methods. Using clinical case history, various dysphagia outcome scales, and/or videofluoroscopy, lower prevalence is being reported in pure cerebellar ataxia such as SCA 6 with 6–50% as opposed to complex cerebellar ataxia such as SCA 3 with 64–74% or Friedreich’s ataxia with up to 100% [1–3, 5, 27, 28]. Videofluoroscopy can detect even subclinical swallowing difficulties and thus leads to higher prevalence estimates [5]. Systematic evaluation of diagnostic procedures and treatment is lacking [29].

Additional to clinical examination in combination with clinical case history, a questionnaire such as the Swal-QOL may be useful as a screening tool in patients with cerebellar ataxia to identify dysphagia and its impact on HRQOL, direct patient care, and further examinations and prevent complications. A
questionnaire in comparison to apparatus-assisted examination is less costly, independent of the clinical setting, better tolerated, and could guide further complex evaluation, e.g., videofluoroscopy to detect silent aspiration [28]. In a recent study, only 63% of dysphagic patients with Friedreich’s ataxia could be admitted to further evaluation by videofluoroscopy, illustrating the difficulty of apparatus-assisted diagnostic procedure for dysphagia in ataxia patients even under study conditions [28]. In that study, dysphagia was evaluated in 60 patients with Friedreich’s ataxia using standardized oromotor assessment and videofluoroscopy, as compared to mainly late onset ataxia patients in our study. The authors focused on silent aspiration, which was found in 34% of patients undergoing videofluoroscopy and was related to repeat-length and two subscores in oromotor assessment, but could not be predicted reliably [28].

Aspiration did not seem to affect swallowing-related quality of life, as no correlation with the Swal-QOL was reported and only 11 of 60 patients (18%) had a total domain score in the Swal-QOL below 70, which we used to identify dysphagic patients. Still, aspiration pneumonia represents one of the major factors for a reduced lifespan in hereditary cerebellar ataxia [13, 30]. The rate of patients experiencing recurrent bronchitis and pneumonia due to aspiration in a long-term study of 23 patients suffering from different forms of cerebellar ataxia was up to 50% and 13% of the patients died of aspiration pneumonia [31]. Thus, the correct diagnosis and recognition of dysphagia cannot be underestimated [29]. For detection of dysphagic symptoms, Swal-QOL and clinical case history should be considered and the Swal-QOL should be used as an additional tool to detect impact on HRQOL.

Dysphagia in neurodegenerative diseases such as cerebellar ataxia, Parkinson’s disease, and Huntington’s disease is known to cause malnutrition, weight loss, and reduced quality of life, but can also threaten a patient’s life [4, 8–11]. In Parkinson’s disease, an impact on quality of life was reported, and in Huntington’s disease, dysphagia correlated with disease severity and overall disability [32, 33]. In cerebellar ataxia, we could now show a correlation with HRQOL, fatigue, depression, and mobility. Disease severity, as rated by walking ability in our cohort,
and Swal-QOL scores were shown to correlate with quality of life and with each other. Still, reduced mobility or gait instability were the most reported and most disabling symptoms in our cohort. Only mobility and dysphagia showed a clear association with HRQOL. We cannot exclude that a present impairment of HRQOL affects answers in the Swal-QOL and vice versa. A possible explanation is the heterogeneity of our cohort with patients mainly suffering from SCA or sporadic ataxia and not a single patient suffering from Friedreich’s ataxia. A subgroup analysis for differences in dysphagia prevalence and correlations was not feasible due to small subgroup sizes.

In neurodegenerative disorders, lower body weight and weight loss have been shown to be correlated with rapid disease progression and worse functional outcome as well as a decrease in subjective quality of life [34–36]. Moreover, in children with ataxia telangiectasia, lower body weight was related to aspiration as assessed with videofluoroscopy [37]. Though weight loss is due to multiple factors, among them medication, motor impairment, intestinal factors, metabolic changes, and dysphagia, in our cohort, we could show unintentional weight loss to mainly occur in dysphagic ataxia patients. We did not find any differences in body mass index in dysphagic as compared to non-dysphagic patients, probably due to the subjective nature of data in a questionnaire. In line with our results, in a study with a long-term follow-up, nine of 19 patients with SCA 1 belonging to one pedigree reported weight loss [38]. Though in adult cerebellar ataxia, to our knowledge, no relation of weight loss and disease progression or outcome has been shown so far, unintentional weight loss and lower body weight in ataxia could be regarded as a potential risk factor for complications and should thus be prevented.

Furthermore, a tendency towards less favorable and more unfavorable nutritional behavior as defined by the German society for nutrition (DGN) in dysphagic patients was seen in our data. The relation of dysphagia and change of nutritional habits was statistically not significant. A larger study would be needed to confirm or reject this observation. The FFL has not been validated for patients with swallowing deficits but is well suited to assess nutritional habits and their deterioration in general. Still, additional questions concerning aspects of food texture and amount of food intake would be helpful for a patient population like ours.

In summary, we could show the Swal-QOL to be an additional useful and simple tool to identify patients with cerebellar ataxia suffering from dysphagia and rate the impact of dysphagia on subjective quality of life. Dysphagia may be a risk factor for unintentional weight loss and a tendency towards unfavorable nutritional behavior, probably leading to more severe complications such as malnutrition and recurrent infections. Our work illustrates the necessity of further prospective studies to investigate the diagnostic work up and impact of correctly diagnosed dysphagia on disease progression, quality of life, and its association with disease severity and possible treatments.

Acknowledgments We are grateful to Dr. Rico NPM Rinkel, VU University Medical Center, Department of Otolaryngology/Head and Neck Surgery, Amsterdam, Netherlands, for sharing his Swal-QOL data with us.

Authors’ Contributions M. Rönnefarth: execution and review of statistical analysis and research project, preparation and writing of the manuscript. N. Hanisch: conception, organization, and execution of the research project; execution of the statistical analysis and review of the manuscript; responsibility for the integrity of the data and the accuracy of the data analysis. A. U. Brandt: design and execution of statistical analysis, organization and conception of the research project, review of the manuscript. A. Mähler: design and execution of FFL and execution of
statistical analysis, organization, and conception of the research project, review of the manuscript. M. Endres: conception of project and project design as well as review of statistics and manuscript. F. Paul: conception of project and project design as well as review of statistics and manuscript. S. Doss: conception and organization of the research project, review of statistics and manuscript, responsibility for the integrity of the data and the accuracy of the data analysis.

Funding Information Open Access funding provided by Projekt DEAL.

Compliance with Ethical Standards
Conflict of Interest M. Rönnefarth, N. Hanisch, and A. Mähler declare that they have no conflict of interest. A. U. Brandt is cofounder of and holds shares in Motognosis GmbH and Nocturne GmbH. He is named as inventor on several patent applications regarding retinal image analysis, perceptive computing, and multiple sclerosis biomarkers. M. Endres reports grants from Bayer, BMBF, Corona Foundation, DFG, DZHK, DZNE, EU, and Foundation Leducq and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Amgen, GSK, Sanofi, Coviden, Novartis, all outside the submitted work. F. Paul is part of the scientific advisory board of Novartis. He reports fees from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire. He is academic editor of PLoS One, associate editor of Neurology® Neuroimmunology & Neuroinflammation; he has been advisor to Sanofi –Genzyme, Biogen Idec, MedImmune, Shire and Alexion; he reports funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, Deutsche Forschungsgemeinschaft, Weth Stiftung in Cologne, Bundesministerium für Bildung und Forschung, Arthur Arinstein Stiftung Berlin, EU FP7 Rahmenprogramm, Guthy Jackson Charitable Foundation and National Multiple Sclerosis of the USA. S. Doss received project funding by DFG, BMBF, teva pharma, Actelion, DHAG (Deutsche Heredo Ataxie Gesellschaft) and Ataxia UK as well as speaker honoraria from Actelion.

Ethical Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (ethics committee at Charité-Universitätsmedizin Berlin (EA1/185/13)) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Jardim LB, Pereira ML, Silveira I, Ferro A, Sequeiros J, Giugliani R. Neurologic findings in Machado-Joseph disease: relation with disease duration, subtypes, and (CAG) n. Arch Neurol. 2001;58(6): 899–904.
2. Schöls L, Krüger R, Amoirdis G, Przuntek H, Epplen JT, Riess O. Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds. J Neurol Neurosurg Psychiatry. 1998;64(1):67–73.
3. Takahashi H, Ishikawa K, Tsutsuami T, Fujigasaki H, Kawata A, Okiyama R, et al. A clinical and genetic study in a large cohort of patients with spinocerebellar ataxia type 6. J Hum Genet. 2004;49(5):556–64.
4. Pedroso JL, Franca MC, Braga-Neto P, D’Abreu A, Sarariva-Pereira ML, Saute JA, et al. Nonmotor and extracerebellar features in Machado-Joseph disease: a review: extracerebellar features in Machado-Joseph disease. Mov Disord. 2013;28(9):1200–8.
5. Isono C, Hirano M, Sakamoto H, Ueno S, Kusunoki S, Nakamura Y. Differences in dysphagia between spinocerebellar ataxia type 3 and type 6. Dysphagia. 2013;28(3):413–8.
6. Rossi M, Perez-Lloret S, Doldan L, Cerquetti D, Balej J, Millar Vernetti P, et al. Autosomal dominant cerebellar ataxias: a systematic review of clinical features. Eur J Neurol. 2014;21(4):607–15.
7. Calvert M, Pall H, Hoppitt T, Eaton B, Savill E, Sackley C. Health-related quality of life and supportive care in patients with rare long-term neurological conditions. Qual Life Res. 2013;22(6):1231–8.
8. Chounard J, Lavigne E, Villeneuve C. Weight loss, dysphagia, and outcome in advanced dementia. Dysphagia. 1998;13(3):151–5.
9. Hudson HM, Daubert CR, Mills RH. The interdependency of protein-energy malnutrition, aging, and dysphagia. Dysphagia. 2000;15(1):31–8.
10. Mendez L, Friedman LS, Castell DO. Swallowing disorders in the elderly. Clin Geriatr Med. 1991;7(2):215–30.
11. Serra-Prat M, Palomera M, Gomez C, Sar-Shalom D, Saiz A, Montoya JG, et al. Oropharyngeal dysphagia as a risk factor for malnutrition and lower respiratory tract infection in independently living older persons: a population-based prospective study. Age Ageing. 2012;41(3):376–81.
12. Barer DH. Dysphagia in acute stroke. Br Med J (Clin Res Ed). 1987;295(6606):1137.
13. Rüb U, Brunt ER, Petrasch-Parwez E, Schöls L, Theegarten D, Auberburg G, et al. Degeneration of ingestion-related brainstem nuclei in spinocerebellar ataxia type 2, 3, 6 and 7. Neuropathol Appl Neurobiol. 2006;32(6):635–49.
14. Logemann JA. Evaluation and treatment of swallowing disorders. San Diego: College-Hill Press; 1983.
15. Schmitz-Hübsch T, Coudert M, Giunti P, Globas C, Baliko L, Fancellu R, et al. Self-rated health status in spinocerebellar ataxia—results from a European multicenter study. Mov Disord. 2010;25(5):587–95.
16. McHorney CA, Robbins J, Lomax K, Rosenbek JC, Chignell K, Kramer AE, et al. The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults. III. Documentation of reliability and validity. Dysphagia. 2002;17(2):97–114.
17. Winkler G, Döring A. Validation of a short qualitative food frequency list used in several German large scale surveys. Z Für Ernährungswissenschaft. 1998;37(3):234–41.
18. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–6.
19. Globas C, du Montcel ST, Baliko L, Boesch S, Depondt C, DiDonato S, et al. Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Mov Disord. 2008;23(15):2232–8.
20. Knupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.
21. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.
22. Flieger F, Alpermann A. Untersuchung der Verständlichkeit des Fragebogens SWAL-QOL (swallowing quality of life). 2012 Mar 15 [cited 2017 Jul 25]; Available from: http://www.schulz-kirchner.de/cgi-bin/eshop/front/shop_main.cgi?func=seachdo&sfidls=&rub1_search=all&sbeg=5-50-2012-01-01.
23. Rosenbek JC, Donovan NJ. Assessment of Behandlungsqualität und der Lebensqualität als Teil eines Repertoires der
Ergebnismessung bei Erwachsenen mit erworbenen Dysphagien. In: Sönke Stanschus (Hg) Rehabilitation von Dysphagien. 1. Aufl. Idstein: Schulz-Kirchner Verlag; 2006. S. 29–36. (Dysphagie Forum; vol. 2).

24. Keage M, Delatycki M, Corben L, Vogel A. A systematic review of self-reported swallowing assessments in progressive neurological disorders. Dysphagia. 2015;30(1):27-46.

25. McHorney CA, Bricker DE, Robbins J, Kramer AE, Rosenbek JC, Chignell KA. The SWAL-QOL outcomes tool for oropharyngeal dysphagia adults: II. Item Reduction and Preliminary Scaling. Dysphagia. 2000;15(3):122–33.

26. Rinkel RN, Verdonck-de Leeuw IM, Langendijk JA, van Reij EJ, Aaronson NK, Leemans CR. The psychometric and clinical validity of the SWAL-QOL questionnaire in evaluating swallowing problems experienced by patients with oral and oropharyngeal cancer. Oral Oncol. 2009;45(8):e67–71.

27. Vogel AP, Brown SE, Folker JE, Corben LA, Delatycki MB. Dysphagia and swallowing-related quality of life in Friedreich ataxia. J Neurol. 2014;261(2):392–9.

28. Keage MJ, Delatycki MB, Gupta I, Corben LA, Vogel AP. Dysphagia in Friedreich ataxia. Dysphagia. 2017.

29. Vogel AP, Keage MJ, Johansson K, Schalling E. Treatment for dysphagia (swallowing difficulties) in hereditary ataxia. Cochrane Database Syst Rev. 2015;11:CD010169.

30. Schroeder SA, Zielen S. Infections of the respiratory system in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2014;49(4):389–99.

31. Ramio-Torrentia I, Gomez E, Genis D. Swallowing in degenerative ataxias. J Neurol. 2006;253(7):875–81.

32. de Tommaso M, Nuzzi A, Delliomonaco AR, Sciruicchio V, Serpino C, Corno C, et al. Dysphagia in Huntington’s disease: correlation with clinical features. Eur Neurol. 2015;74(1–2):49–53.

33. Carneiro D, das Graças Wanderley de Sales Corio M, Belo LR, de Marcos Rabelo AR, Asano AG, Lins OG. Quality of life related to swallowing in Parkinson’s disease. Dysphagia. 2014;29(5):578–82.

34. Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, et al. Factors associated with slow progression in Huntington’s disease. Arch Neurol. 1991;48(8):800–4.

35. Wills A-MA, Pérez A, Wang J, Su X, Morgan J, Rajan SS, et al. Association between change in body mass index, unified Parkinson’s disease rating scale scores, and survival among persons with Parkinson disease: secondary analysis of longitudinal data from NINDS exploratory trials in Parkinson disease long-term study I. JAMA Neurol. 2016;73(3):321–8.

36. Akbar U, He Y, Dai Y, Hack N, Malaty I, McFarland NR, et al. Weight loss and impact on quality of life in Parkinson’s disease. Fasano A, editor. PLoS One. 2015;10(5):e0124541.

37. Lefton-Greif MA, Crawford TO, Winkelstein JA, Loughlin GM, Koerner CB, Zahurak M, et al. Oropharyngeal dysphagia and aspiration in patients with ataxia-telangiectasia. J Pediatr. 2000;136(2):225–31.

38. Genis D, Matilla T, Volpini V, Rosell J, Dvalos A, Ferrer I, et al. Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred (CAG) n expansion and early premonitory signs and symptoms. Neurology. 1995;45(1):24–30.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.